Literature DB >> 15756227

Central nervous system hyperexcitability associated with glutamate dehydrogenase gain of function mutations.

David M Raizen1, Amy Brooks-Kayal, Linda Steinkrauss, Gihan I Tennekoon, Charles A Stanley, Andrea Kelly.   

Abstract

OBJECTIVE: To describe seizure phenotypes associated with the hyperinsulinism/hyperammonemia syndrome (HI/HA), which is caused by gain of function mutations in the enzyme glutamate dehydrogenase (GDH). STUDY
DESIGN: A retrospective review of records of 14 patients with HI/HA.
RESULTS: Nine patients had seizures as the first symptom of HI/HA, and six had seizures in the absence of hypoglycemia. No electroencephalogram (EEG) background abnormalities were identified. In four patients, EEG recordings during seizures in the setting of normal blood glucose contained generalized epileptiform discharges. EEGs of three of these patients showed 0.5- to 2-second generalized irregular spike-and-wave discharge at 3 to 6 Hz corresponding to eye blinks, eye rolling, or staring. The EEG of the fourth patient consisted of 20 seconds of generalized regular spike-and-wave discharge at 3 Hz in the clinical context of staring and unresponsiveness. In two patients, seizure control worsened with carbamezapine or oxcarbezapine treatment.
CONCLUSIONS: In patients with HI/HA, generalized seizures are common and can occur in the absence of hypoglycemia. The drugs carbamazepine and oxcarbazepine should be used with caution for treatment. Pathogenesis of epilepsy in these patients may be related to effects of GDH mutations in the brain, perhaps in combination with effects of recurrent hypoglycemia and chronic hyperammonemia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15756227     DOI: 10.1016/j.jpeds.2004.10.040

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  15 in total

Review 1.  Perspective on the Genetics and Diagnosis of Congenital Hyperinsulinism Disorders.

Authors:  Charles A Stanley
Journal:  J Clin Endocrinol Metab       Date:  2016-02-23       Impact factor: 5.958

Review 2.  Two genetic forms of hyperinsulinemic hypoglycemia caused by dysregulation of glutamate dehydrogenase.

Authors:  Charles A Stanley
Journal:  Neurochem Int       Date:  2010-12-02       Impact factor: 3.921

Review 3.  Treatable Genetic Metabolic Epilepsies.

Authors:  Lama Assi; Youssef Saklawi; Pascale E Karam; Makram Obeid
Journal:  Curr Treat Options Neurol       Date:  2017-09       Impact factor: 3.598

Review 4.  The hyperinsulinism/hyperammonemia syndrome.

Authors:  Andrew A Palladino; Charles A Stanley
Journal:  Rev Endocr Metab Disord       Date:  2010-09       Impact factor: 6.514

Review 5.  Glutamate dehydrogenase in brain mitochondria: do lipid modifications and transient metabolon formation influence enzyme activity?

Authors:  Mary C McKenna
Journal:  Neurochem Int       Date:  2011-07-13       Impact factor: 3.921

Review 6.  Regulation of glutamate metabolism and insulin secretion by glutamate dehydrogenase in hypoglycemic children.

Authors:  Charles A Stanley
Journal:  Am J Clin Nutr       Date:  2009-07-22       Impact factor: 7.045

7.  Glutamate dehydrogenase 1 and SIRT4 regulate glial development.

Authors:  Daniel Komlos; Kara D Mann; Yue Zhuo; Christopher L Ricupero; Ronald P Hart; Alice Y-C Liu; Bonnie L Firestein
Journal:  Glia       Date:  2012-12-22       Impact factor: 7.452

Review 8.  What's new in metabolic and genetic hypoglycaemias: diagnosis and management.

Authors:  Vassili Valayannopoulos; Stéphane Romano; Karine Mention; Anne Vassault; Daniel Rabier; Michel Polak; Jean-Jacques Robert; Yves de Keyzer; Pascale de Lonlay
Journal:  Eur J Pediatr       Date:  2007-10-03       Impact factor: 3.183

Review 9.  Congenital hyperinsulinism: current trends in diagnosis and therapy.

Authors:  Jean-Baptiste Arnoux; Virginie Verkarre; Cécile Saint-Martin; Françoise Montravers; Anaïs Brassier; Vassili Valayannopoulos; Francis Brunelle; Jean-Christophe Fournet; Jean-Jacques Robert; Yves Aigrain; Christine Bellanné-Chantelot; Pascale de Lonlay
Journal:  Orphanet J Rare Dis       Date:  2011-10-03       Impact factor: 4.123

10.  Anticonvulsant drugs, brain glutamate dehydrogenase activity and oxygen consumption.

Authors:  Lourdes A Vega Rasgado; Guillermo Ceballos Reyes; Fernando Vega-Díaz
Journal:  ISRN Pharmacol       Date:  2012-03-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.